<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593814</url>
  </required_header>
  <id_info>
    <org_study_id>AAA 04-04</org_study_id>
    <nct_id>NCT00593814</nct_id>
  </id_info>
  <brief_title>GORE EXCLUDER速 Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms</brief_title>
  <official_title>A Clinical Evaluation of the GORE EXCLUDER速 Bifurcated Endoprosthesis - Low Permeability in the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of the GORE EXCLUDER速 Bifurcated
      Endoprosthesis-Low Permeability in the primary treatment of infrarenal abdominal aortic
      aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Efficacy Events</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE EXCLUDER速 Bifurcated Endoprosthesis-Low Permeability</intervention_name>
    <description>Implant</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infrarenal Abdominal Aortic Aneurysms less than 4.5 cm in diameter

          2. Anatomy meets EXCLUDER Bifurcated Endoprosthesis - Low Permeability specification
             criteria per Instructions for Use

          3. Access vessel able to receive 18 French introducer sheath

          4. Life expectancy &gt; 2 years

          5. Appropriate candidate for endovascular repair

          6. Ability to comply with protocol requirements including follow-up

          7. 21 years of age or older, male or infertile female**

        Exclusion Criteria:

          1. Mycotic or ruptured aneurysm

          2. Participating in another investigational device or drug study within one year

          3. Documented history of drug abuse within six months

          4. Myocardial infarction or cerebral vascular accident within six weeks

          5. Pulmonary insufficiency requiring chronic home oxygen or inability to ambulate due to
             pulmonary function

          6. Iliac anatomy that would require occlusion of both internal iliac arteries

          7. Planned occlusion or reimplantation of significant mesenteric or renal arteries

          8. Planned concomitant surgical procedure or previous major surgery within 30 days

          9. Previous prosthesis placement in the aorta or iliac arteries

         10. Degenerative connective tissue disease (e.g., Marfan's and Ehlers Danlos Syndrome)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark F Fillinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 13, 2010</lastchanged_date>
  <firstreceived_date>December 20, 2007</firstreceived_date>
  <firstreceived_results_date>April 20, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Lanesha Hill</name_title>
    <organization>WL Gore &amp; Associates</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EXCLUDER Low Permeability</title>
          <description>Modified EXCLUDER device with Low Permeability Layer designed to treat abdominal aortic aneurysms with an endovascular surgical technique. This device functions identically to the original EXCLUDER device, however, a low permeability film is included in the device to eliminate migration of serous fluid through the graft.</description>
        </group>
        <group group_id="P2">
          <title>Original EXCLUDER</title>
          <description>Historical Sample from original study of EXCLUDER Device. The original EXCLUDER Device was designed for the endovascular treatment of abdominal aortic aneurysms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EXCLUDER Low Permeability</title>
          <description>Modified EXCLUDER device with Low Permeability Layer designed to treat abdominal aortic aneurysms with an endovascular surgical technique. This device functions identically to the original EXCLUDER device, however, a low permeability film is included in the device to eliminate migration of serous fluid through the graft.</description>
        </group>
        <group group_id="B2">
          <title>Original EXCLUDER</title>
          <description>Historical Sample from original study of EXCLUDER Device. The original EXCLUDER Device was designed for the endovascular treatment of abdominal aortic aneurysms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="120"/>
                <measurement group_id="B3" value="259"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.9" spread="7.5"/>
                <measurement group_id="B2" value="72.6" spread="7.7"/>
                <measurement group_id="B3" value="73.3" spread="7.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
                <measurement group_id="B2" value="106"/>
                <measurement group_id="B3" value="218"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="120"/>
                <measurement group_id="B3" value="259"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure</title>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>EXCLUDER Low Permeability</title>
            <description>Modified EXCLUDER device with Low Permeability Layer designed to treat abdominal aortic aneurysms with an endovascular surgical technique. This device functions identically to the original EXCLUDER device, however, a low permeability film is included in the device to eliminate migration of serous fluid through the graft.</description>
          </group>
          <group group_id="O2">
            <title>Original EXCLUDER</title>
            <description>Historical Sample from original study of EXCLUDER Device. The original EXCLUDER Device was designed for the endovascular treatment of abdominal aortic aneurysms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Efficacy Events</title>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EXCLUDER Low Permeability</title>
          <description>Modified EXCLUDER device with Low Permeability Layer designed to treat abdominal aortic aneurysms with an endovascular surgical technique. This device functions identically to the original EXCLUDER device, however, a low permeability film is included in the device to eliminate migration of serous fluid through the graft.</description>
        </group>
        <group group_id="E2">
          <title>Original EXCLUDER</title>
          <description>Historical Sample from original study of EXCLUDER Device. The original EXCLUDER Device was designed for the endovascular treatment of abdominal aortic aneurysms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Endoleak</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Unplanned Branch Vessel Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in Aneurysm Diameter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tab Bonny</name_or_title>
      <organization>W.L. Gore and Associates</organization>
      <phone>928 864 4275</phone>
      <email>tbonny@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
